Trials / Completed
CompletedNCT02228590
A Study to Examine APL-130277 in Patients With Parkinson's Disease
A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy, tolerability and safety of single treatments of APL-130277 in 16 patients with Parkinson's Disease (PD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APL-130277 | Apomorphine Hydrochloride, Sublingual Thin Film |
Timeline
- Start date
- 2014-08-31
- Primary completion
- 2014-11-24
- Completion
- 2014-11-24
- First posted
- 2014-08-29
- Last updated
- 2020-07-30
- Results posted
- 2020-07-30
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02228590. Inclusion in this directory is not an endorsement.